Loading clinical trials...
Loading clinical trials...
The primary goal of hepatitis C virus (HCV) Direct Acting Antivirals (DAAs) is to achieve undetectable HCV RNA in the blood. A response that should be maintained for at least 12 weeks from completion ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Alexandria University
NCT06615479 · Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
NCT06678659 · Unresectable, Locally Advanced, and more
NCT07320235 · Relapsed Acute Myeloid Leukemia
NCT05865002 · Relapsed Malignant Solid Neoplasm
Alexandria University.
Alexandria
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions